EGFR and neoplasm: Molecular analyses revealed that the tumor was negative for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements and that >90% of the tumor cells expressed programmed death ligand 1 (PD‐L1).